Supplementary material 4 - Enhancers.xlsx

	A	B	C	D	E	F	G	H	I	J
1	Table S6: Variants overlapping with enhancer elements. Positions are shown in hg38.
2	rsID	Chr	Position	Enhancer ID	Enhancer type	Enhancer start location	Enhancer end location	P-value	Collapsed trait	Study Disease/Trait
3	rs12061931	chr1	3779792	EH38D4333212	dELS,CTCF-bound	3779613	3779811	6.00E-08	OC	Ovarian cancer
4	rs143623984	chr1	101301117	EH38D2204327	dELS	101300977	101301315	9.00E-06	OC	Ovarian cancer
5	rs1763604	chr1	16013277	EH38D4346634	dELS,CTCF-bound	16013273	16013496	7.00E-09	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
6	rs186507655	chr1	1351675	EH38D4328650	dELS	1351662	1352006	5.00E-10	Morbidity pleio	Cancer (pleiotropy)
7	rs3754464	chr1	159009146	EH38D2228820	pELS	159008798	159009147	2.00E-06	EOC	Epithelial ovarian cancer
8	rs3820282	chr1	22141722	EH38D2137313	pELS	22141531	22141863	2.00E-08	EOC	Epithelial ovarian cancer
9	rs5780234	chr1	204379514	EH38D2265364	pELS	204379220	204379567	6.00E-06	Prog free surv w/trt	Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel
10	rs77548871	chr1	155016057	EH38D2225189	pELS,CTCF-bound	155015955	155016114	5.00E-09	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
11	rs9442387	chr1	1175206	EH38D2115887	pELS	1175187	1175440	8.00E-06	EOC	Epithelial ovarian cancer
12	rs2615880	chr10	115937294	EH38D2395398	dELS	115937265	115937580	8.00E-06	OC	Ovarian cancer
13	rs8187707	chr10	99850776	EH38D4543906	dELS	99850754	99850969	5.00E-06	Trt response	Carboplatin disposition in epthelial ovarian cancer
14	rs870274	chr10	122120548	EH38D2400961	dELS,CTCF-bound	122120395	122120632	7.00E-06	EOC	Epithelial ovarian cancer
15	rs118151305	chr11	66324772	EH38D4614798	dELS	66324708	66325053	6.00E-09	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
16	rs141131642	chr11	10778732	EH38D4582909	dELS,CTCF-bound	10778576	10778906	5.00E-06	EOC	Epithelial ovarian cancer
17	rs2237896	chr11	2837210	EH38D4577192	dELS,CTCF-bound	2837114	2837461	5.00E-09	Morbidity pleio	Cancer
18	rs67812265	chr11	57776189	EH38D4605660	dELS	57776072	57776229	6.00E-06	EOC	Epithelial ovarian cancer
19	rs72932523	chr11	69138652	EH38D4618730	dELS,CTCF-bound	69138329	69138674	1.00E-09	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
20	rs78540526	chr11	69516650	EH38D2464446	dELS	69516544	69516889	1.00E-15	Morbidity pleio	Cancer
21	rs7937840	chr11	62126500	EH38D4609013	dELS	62126353	62126577	2.00E-09	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
22	rs11175194	chr12	63871057	EH38D2569224	pELS,CTCF-bound	63870922	63871146	1.00E-07	EOC	Epithelial ovarian cancer
23	rs3184504	chr12	111446804	EH38D4729157	dELS	111446721	111446984	1.00E-06	Morbidity pleio	Cancer (pleiotropy)
24	rs7953249	chr12	120965921	EH38D4736493	dELS,CTCF-bound	120965684	120965970	8.00E-07	HGSOC	High-grade serous ovarian cancer
25	rs56404467	chr13	32265853	EH38D2638499	dELS	32265771	32266114	1.00E-07	Morbidity pleio	Cancer
26	rs78375425	chr13	39329007	EH38D2643996	dELS	39328854	39329025	3.00E-06	OC	Ovarian cancer
27	rs17211649	chr14	20698124	EH38D2697839	dELS,CTCF-bound	20697788	20698128	2.00E-06	Trt response	Paclitaxel disposition in epithelial ovarian cancer
28	rs2277509	chr14	91283251	EH38D4838462	dELS	91282958	91283306	2.00E-11	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
29	rs4313770	chr15	38490292	EH38D4865775	dELS	38490248	38490589	6.00E-06	Trt response	Carboplatin disposition in epthelial ovarian cancer
30	rs8060270	chr16	73418955	EH38D2882116	pELS	73418766	73419108	3.00E-06	EOC	Epithelial ovarian cancer
31	rs11263763	chr17	37743574	EH38D5007720	pELS,CTCF-bound	37743514	37743844	2.00E-08	Morbidity pleio	Cancer
32	rs117529210	chr17	30841062	EH38D5002529	dELS	30840796	30841141	5.00E-10	Obesity pleio	Leg fat ratio or ovarian cancer (pleiotropy)
33	rs12601991	chr17	37741642	EH38D5007714	dELS	37741463	37741665	1.00E-09	Morbidity pleio	Cancer
34	rs139505845	chr17	57289728	EH38D5025342	dELS	57289720	57289972	6.00E-06	OC	Ovarian cancer (MTAG)
35	rs199512	chr17	46779986	EH38D5017671	dELS	46779785	46780023	3.00E-15	Morbidity pleio	Ovarian cancer or critical COVID-19 (pleiotropy)
36	rs244353	chr17	55117408	EH38D5024032	dELS	55117205	55117547	1.00E-31	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
37	rs591939	chr17	42546057	EH38D5012971	pELS	42545860	42546141	3.00E-08	Obesity pleio	Waist-to-hip ratio or ovarian cancer (pleiotropy)
38	rs70602	chr17	46782349	EH38D5017675	dELS,CTCF-bound	46782257	46782562	6.00E-14	Morbidity pleio	Ovarian cancer or hospitalized COVID-19 (pleiotropy)
39	rs7209484	chr17	48065680	EH38D5018942	pELS	48065439	48065752	1.00E-10	Obesity pleio	Arm fat ratio or ovarian cancer (pleiotropy)
40	rs75637630	chr17	30841060	EH38D5002529	dELS	30840796	30841141	7.00E-11	Obesity pleio	Trunk fat ratio or ovarian cancer (pleiotropy)
41	rs9302891	chr17	69228706	EH38D5035407	dELS,CTCF-bound	69228643	69228954	7.00E-06	Trt response	Paclitaxel disposition in epithelial ovarian cancer
42	rs470903	chr18	77003313	EH38D3027353	dELS,CTCF-bound	77003133	77003359	3.00E-06	Trt response	Paclitaxel disposition in epithelial ovarian cancer
43	rs1469713	chr19	19417997	EH38D5119877	dELS	19417691	19418038	1.00E-10	Morbidity pleio	Breast cancer, ovarian cancer or prostate cancer (pleiotropy)
44	rs17513613	chr19	29795915	EH38D3053388	dELS	29795778	29796115	1.00E-09	Obesity pleio	Body mass index or ovarian cancer (pleiotropy)
45	rs2363956	chr19	17283315	EH38D5116678	pELS,CTCF-bound	17283062	17283323	1.00E-07	OC	Ovarian cancer
46	rs34357515	chr19	3197622	EH38D5100061	dELS	3197441	3197677	1.00E-06	EOC	Epithelial ovarian cancer
47	rs112420119	chr2	44805022	EH38D3117248	dELS,CTCF-bound	44804886	44805117	4.00E-06	Prog free surv w/trt	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
48	rs2072590	chr2	176177905	EH38D5258659	pELS,CTCF-bound	176177810	176178047	5.00E-11	OC	Ovarian cancer
49	rs2594950	chr2	176643894	EH38D3213284	dELS,CTCF-bound	176643739	176644020	7.00E-06	MOC	Mucinous epithelial ovarian cancer
50	rs3769823	chr2	201258272	EH38D5270452	pELS,CTCF-bound	201258267	201258615	1.00E-16	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
51	rs4848599	chr2	120481784	EH38D5229053	dELS	120481525	120481839	9.00E-09	Morbidity pleio	Cancer
52	rs537364753	chr2	184453308	EH38D3219207	dELS,CTCF-bound	184453065	184453329	6.00E-06	OC	Ovarian cancer
53	rs6748345	chr2	67269079	EH38D5198997	dELS	67268839	67269135	2.00E-08	Obesity pleio	Waist-to-hip ratio or ovarian cancer (pleiotropy)
54	rs6755777	chr2	176178498	EH38D3212858	pELS,CTCF-bound	176178433	176178582	5.00E-13	HGSOC	High-grade serous ovarian cancer
55	rs67654717	chr2	15170390	EH38D3091057	dELS	15170365	15170522	9.00E-06	Prog free surv	Progression free survival in epithelial ovarian cancer
56	rs711830	chr2	176172583	EH38D5258649	dELS,CTCF-bound	176172350	176172666	5.00E-08	BOT	Serous borderline ovarian cancer
57	rs72831838	chr2	113258824	EH38D5225311	dELS	113258701	113259029	8.00E-07	MOC	Mucinous ovarian carcinoma
58	rs7559097	chr2	38517625	EH38D5182203	pELS	38517388	38517705	6.00E-06	EOC	Epithelial ovarian cancer
59	rs895412	chr2	113216387	EH38D5225261	dELS,CTCF-bound	113216266	113216417	1.00E-07	HGSOC	High-grade serous epithelial ovarian cancer
60	rs6062344	chr20	64064671	EH38D5354508	pELS	64064404	64064736	5.00E-10	Obesity pleio	Waist-to-hip ratio or ovarian cancer (pleiotropy)
61	rs2070368	chr21	34708100	EH38D5365763	dELS,CTCF-bound	34707928	34708277	1.00E-08	NMOC	Non-mucinous epithelial ovarian cancer
62	rs135573	chr22	46131359	EH38D5412024	dELS,CTCF-bound	46131139	46131476	3.00E-06	EOC	Epithelial ovarian cancer
63	rs5993791	chr22	19681497	EH38D5382290	dELS,CTCF-bound	19681368	19681711	8.00E-06	EOC	Epithelial ovarian cancer
64	rs11130471	chr3	55376983	EH38D5456713	dELS	55376778	55377125	9.00E-06	Trt response	Carboplatin disposition in epthelial ovarian cancer
65	rs13097957	chr3	156638368	EH38D3505467	dELS	156638277	156638563	1.00E-09	Obesity pleio	Body mass index or ovarian cancer (pleiotropy)
66	rs1728807	chr3	11007643	EH38D5425620	dELS,CTCF-bound	11007593	11007900	9.00E-06	EOC	Epithelial ovarian cancer
67	rs1875108	chr3	55592887	EH38D5456870	dELS	55592648	55592940	5.00E-06	Prog free surv	Progression free survival in serous epithelial ovarian cancer
68	rs7631664	chr3	4709568	EH38D5421499	dELS	4709410	4709668	9.00E-10	Overall surv	Overall survival in ovarian cancer
69	rs9841147	chr3	197379538	EH38D3537923	dELS,CTCF-bound	197379345	197379591	3.00E-06	Prog free surv	Progression free survival in serous epithelial ovarian cancer
70	rs9870207	chr3	190807727	EH38D5525764	dELS,CTCF-bound	190807700	190808049	3.00E-06	EOC	Epithelial ovarian cancer
71	rs9878602	chr3	71486187	EH38D5465393	dELS	71485958	71486262	4.00E-08	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
72	rs10009522	chr4	153242242	EH38D3643462	dELS,CTCF-bound	153242234	153242574	9.00E-06	EOC	Epithelial ovarian cancer
73	rs12233670	chr4	38785595	EH38D5557464	dELS,CTCF-bound	38785431	38785764	8.00E-12	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
74	rs7671665	chr4	119026033	EH38D3619844	pELS	119025928	119026274	4.00E-08	Obesity pleio	Waist-to-hip ratio adjusted for body mass index or ovarian cancer (pleiotropy)
75	rs80192073	chr4	40121779	EH38D3569064	dELS,CTCF-bound	40121536	40121879	1.00E-06	EOC	Epithelial ovarian cancer
76	rs148570926	chr5	139690696	EH38D5691509	dELS,CTCF-bound	139690451	139690800	3.00E-06	OC	Ovarian cancer
77	rs1862626	chr5	56737113	EH38D5649792	dELS	56736919	56737264	4.00E-12	Morbidity pleio	Cancer (pleiotropy)
78	rs60982503	chr5	180485036	EH38D3801525	dELS,CTCF-bound	180484928	180485122	5.00E-06	OC	Ovarian cancer
79	rs7725218	chr5	1282299	EH38D3669797	dELS	1282182	1282402	2.00E-10	Morbidity pleio	Cancer (pleiotropy)
80	rs830888	chr5	52727882	EH38D3701384	dELS,CTCF-bound	52727658	52728003	1.00E-08	Morbidity pleio	Cancer
81	rs303051	chr6	10403963	EH38D3811908	pELS,CTCF-bound	10403626	10403975	6.00E-06	OC	Ovarian cancer
82	rs74375290	chr6	31129248	EH38D5743011	dELS,CTCF-bound	31129223	31129427	6.00E-06	EOC	Epithelial ovarian cancer
83	rs10260419	chr7	11524758	EH38D5831153	dELS	11524532	11524872	1.00E-07	EOC	Epithelial ovarian cancer
84	rs2525548	chr7	99955544	EH38D5878904	dELS	99955252	99955598	3.00E-09	Morbidity pleio	Cancer
85	rs78503057	chr7	23357410	EH38D5836959	dELS,CTCF-bound	23357320	23357666	1.00E-06	Prog free surv w/trt	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
86	rs12546957	chr8	127619425	EH38D4147481	dELS	127619420	127619731	3.00E-06	EOC	Epithelial ovarian cancer
87	rs12682374	chr8	127398703	EH38D5988275	pELS	127398393	127398741	9.00E-29	Morbidity pleio	Cancer
88	rs150293538	chr8	76408119	EH38D5961710	pELS	76408010	76408195	2.00E-09	BOT	Low-grade serous and serous borderline ovarian cancer
89	rs202280	chr8	81290982	EH38D5963979	dELS,CTCF-bound	81290877	81291065	6.00E-06	Overall surv w/trt	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
90	rs7017073	chr8	128192016	EH38D5989217	dELS	128191948	128192276	4.00E-14	Morbidity pleio	Breast cancer or ovarian cancer (pleiotropy)
91	rs9886651	chr8	127805637	EH38D5988734	dELS	127805521	127805775	2.00E-09	EOC	Epithelial ovarian cancer
92	rs11244061	chr9	133278537	EH38D6076271	dELS,CTCF-bound	133278511	133278661	1.00E-09	Morbidity pleio	Ovarian cancer or hospitalized COVID-19 (pleiotropy)
93	rs12551733	chr9	16895580	EH38D6015251	dELS	16895302	16895635	4.00E-16	Obesity pleio	Leg fat ratio or ovarian cancer (pleiotropy)
94	rs1413299	chr9	98998959	EH38D6048994	dELS,CTCF-bound	98998910	98999133	2.00E-08	EOC	Epithelial ovarian cancer
95	rs554833	chr9	133271745	EH38D4248338	dELS	133271669	133271930	1.00E-88	Morbidity pleio	Ovarian cancer or COVID-19 infection (pleiotropy)
96	rs56343119	chr9	133370796	EH38D6076427	dELS	133370761	133371102	1.00E-22	Morbidity pleio	Ovarian cancer or COVID-19 infection (pleiotropy)
97	rs6479436	chr9	92905580	EH38D6043480	dELS,CTCF-bound	92905380	92905597	7.00E-07	Prog free surv w/trt	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
98	rs79925169	chr9	89469330	EH38D6040458	dELS,CTCF-bound	89469053	89469337	5.00E-06	EOC	Epithelial ovarian cancer
99	rs17338346	chrX	31133020	EH38D4272730	dELS	31132791	31133128	1.00E-05	Prog free surv w/trt	Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel
100	rs972834	chrX	23276803	EH38D4269084	dELS	23276523	23276872	7.00E-06	OC	Ovarian cancer (MTAG)